Kuantum Papers is an integrated pulp and paper manufacturer in Punjab, India, producing writing and printing paper (Maplitho, copier, specialty) from a 50-50 mix of agro residue (wheat straw) and wood pulp. It operates four paper machines with a current capacity of about 540 tons per day, and has integrated pulp, chemical recovery, and captive PCC production. The writing and printing paper segment is competitive, with imports from China and Indonesia pressuring prices, but Kuantum holds a strong position with a dealer network of over 100 partners and a location advantage that gives it among the highest realizations in the market. Its FY26 EBITDA margin was 14.8% (EBITDA of INR162 crores), and Q1 FY27 came in at 13.2% (EBITDA of INR40 crores) due to elevated raw material and energy costs. The margin level is average for the industry, but management targets 18-20% as volumes scale and the product mix shifts toward specialty grades.
The economics persist because of integration and raw material control. Kuantum's social farm forestry program covers 19,650 acres with 19,100 farmers, and it targets distributing 1 crore high-yielding saplings per year within three years, ensuring wood supply at competitive prices. Its agro pulp capability allows it to use wheat straw, which is abundant in Punjab, and it has storage infrastructure to manage price volatility. The specialty paper portfolio, including oil and grease resistant paper, requires qualification cycles and offers import substitution; specialty grades currently make up 18-19% of revenue and are targeted to reach 30% with EBITDA margins around 20%. The company is also among the highest priced in the market, indicating pricing power, and it has long-standing dealer relationships spanning three generations. However, the industry faces import dumping risk, and the company has filed anti-dumping and anti-subsidy applications for writing and printing paper, with the anti-subsidy application expected to be processed by FY27 year-end.
The inflection is the completion of the PM3 rebuild, now expected by September 2026 (delayed from June due to import parts), which will bring all four machines to peak capacity. PM1 was rebuilt in December 2025, adding about 20 tons per day, and PM2 was rebuilt in March 2026, lifting capacity to 75 tons per day. The total capacity will rise to about 650-675 tons per day, enabling a 40-50% volume increase to 2.3 lakh tons annually. Management guides FY27 revenue to 1300+ crores and FY28 to 1400-1500 crores, with EBITDA margin of 16-18% by end of FY27 (from Q3 onwards) and 18-20% in the medium term. Specialty paper share is targeted to reach 30% of production, and the AI-based Project Nirmaan is expected to reduce manufacturing costs by 4-5% by March 2028. Debt is expected to peak at around INR760-770 crores in FY27, then reduce by INR170-175 crores per year to under INR300 crores in three years. By mid-2028, the business should be running at 95%+ capacity utilization, with revenue around INR1,500 crores, EBITDA around INR300 crores (at 20% margin), and a significantly lower debt burden.
Management has a track record of delivering on capacity upgrades, though with some slippage. In November 2025, they committed to PM1 by December 2025, PM2 by January 2026, and PM3 by March 2026; PM1 and PM2 were completed on time, but PM3 slipped to September 2026 due to imported parts. They have consistently raised guidance: from "better performance" in FY27 to specific targets of 1300+ crores revenue and 16-18% EBITDA margin by Q3 FY27. They have also maintained the volume growth target of 40-50% for FY27. Capital allocation is focused on debt reduction: they plan to repay INR170-175 crores per year, and have deferred the tissue paper plant until debt is under control. They are exploring cheaper funding options, including FCNRB loans and equity raising (rights/QIP), to lower the cost of funds, which is currently around 8.5% for long-term debt. The Q1 FY27 EBITDA margin of 13.2% was below the FY26 level of 14.8%, but management attributes this to West Asia conflict-driven cost inflation and expects a recovery from Q3 as wheat straw prices ease and the PM3 rebuild adds higher-margin volume.
The earnings path is visible: FY27 revenue of 1300+ crores at 16-18% EBITDA margin implies EBITDA of INR210-235 crores, and FY28 revenue of 1400-1500 crores at 18-20% implies EBITDA of INR250-300 crores. Debt repayment of INR170-175 crores per year is supported by internal accruals. For this to hold, PM3 must commission by September 2026 and reach stable operations, wheat straw prices must correct (they are currently elevated due to floods and fuel competition), and specialty paper share must ramp to 30% with 20% EBITDA margins. The key watchpoint is the execution of the PM3 rebuild and the ability to achieve 95%+ capacity utilization. The tension between Q1 FY27 margin decline and the full-year guidance is resolved by management's expectation of cost normalization and price hikes; if raw material costs remain high or PM3 is further delayed, the margin target will be missed. The single most important falsifier is a sustained failure to lift EBITDA margin above 15% by Q3 FY27, which would indicate that the cost inflation is structural rather than temporary.
companyname: Kuantum Papers Limited ticker: KUANTUM sector: Pulp & Paper / Writing & Printing Paper Manufacturing Kuantum Papers is a writing and printing paper manufacturer based in Saila Khurd, Hoshiarpur, Punjab. It was established in 1980 and operates a fully backward-integrated plant on 259 acres, controlling everything from raw material sourcing through agro and wood pulping, papermaking, chemical recovery, and power generation (Annual Report FY26). The company runs four paper machines w...
Read the full report →capex, margin expansion, new product segment, debt reduction
FY27 revenue guided at INR1,600-1,700 crores with 40-50% volume growth to 2.3 lakh tons driven by capacity expansion and operational efficiency; EBITDA margin target of 18-20%
Guidance upgradedGet valuation models, detailed research reports, thematic primers, one-pagers, risk analysis, growth triggers, bear case, capex tracker, walk the talk, and more for Kuantum Papers Limited and 4,900+ companies.
5-day free pass. No card required.